Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-25-049542
Filing Date
2025-05-15
Accepted
2025-05-15 16:42:18
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 11382
2 EXHIBIT A tm2515190d1_exa.htm EX-99.A 4359
  Complete submission text file 0001104659-25-049542.txt   17503
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Subject) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-42217 | Film No.: 25954527
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 6100 N. WESTERN AVE OKLAHOMA CITY OK 73118
Business Address
Konar Shameek (Filed by) CIK: 0001465302 (see all company filings)

Type: SCHEDULE 13G